Search research articles
Contact Us
Filters
Showing results (101-110 of 103) with videos related to
Page
of 11
Sort By:
You have reached the last page of results.
This site can display upto 103 results.
Nature Medicine
|
April 14, 2026
Elraglusib and chemotherapy in metastatic pancreatic ductal adenocarcinoma: a randomized controlled phase 2 trial
Devalingam Mahalingam, Rachna T Shroff, Benedito A Carneiro, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 21, 2026
Camonsertib, an ATRi, in Combination with Low-Dose Gemcitabine in Solid Tumors with DNA Damage Response (DDR) Aberrations: Preclinical and Phase 1b Results
Ezra Y Rosen, Timothy A Yap, Elisa Fontana, et al.
Cell Reports. Medicine
|
April 1, 2025
TIMEPOINT, a phase 1 study combining MTL-CEBPA with pembrolizumab, supports the immunomodulatory effect of MTL-CEBPA in solid tumors
Ruth Plummer, Mikael H Sodergren, Rose Hodgson, et al.
Page
of 11
Search research articles
Search
Showing results (101-110 of 103) with videos related to
Sort By:
Page
of 11
You have reached the last page of results.
This site can display upto 103 results.
Nature Medicine
|
April 14, 2026
Elraglusib and chemotherapy in metastatic pancreatic ductal adenocarcinoma: a randomized controlled phase 2 trial
Devalingam Mahalingam, Rachna T Shroff, Benedito A Carneiro, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 21, 2026
Camonsertib, an ATRi, in Combination with Low-Dose Gemcitabine in Solid Tumors with DNA Damage Response (DDR) Aberrations: Preclinical and Phase 1b Results
Ezra Y Rosen, Timothy A Yap, Elisa Fontana, et al.
Cell Reports. Medicine
|
April 1, 2025
TIMEPOINT, a phase 1 study combining MTL-CEBPA with pembrolizumab, supports the immunomodulatory effect of MTL-CEBPA in solid tumors
Ruth Plummer, Mikael H Sodergren, Rose Hodgson, et al.
Page
of 11